Study strengthens link between HHV-6B and mesial temporal lobe epilepsy

HHV-6 FoundationJun 15 2012

Could antiviral treatment prevent some cases of epilepsy?

A ten-year NIH-funded study has determined that a third of infants with prolonged seizures and fever suffer from either a new or reactivated roseola virus infection. Roseola viruses are the cause of the common childhood rash, but can also cause limbic encephalitis, a condition that frequently progresses to epilepsy. Investigators discovered one of the roseola viruses, human herpesvirus-6B (HHV-6B) in the blood of 32% of 169 infants with prolonged seizures, a condition known as status epilepticus. They found HHV-7 (another roseola virus) in 7.1% of the patients, usually as a co-infection with HHV-6B.

The study strengthens the link between HHV-6B and mesial temporal lobe epilepsy. HHV-6B is the primary cause of limbic encephalitis in transplant patients and half of those cases go on to develop epilepsy within 3-5 years. Furthermore, several studies have found HHV-6B DNA at high levels in the brain tissue of patients with refractory epilepsy. "A clinical trial is urgently needed to determine if repeat seizures and some cases of temporal lobe epilepsy might be prevented using existing antiviral therapy," said Kristin Loomis, executive director of the HHV-6 Foundation.

These viruses persist in the brain cells and can be activated during periods of immunosuppression or stress. HHV-6 and HHV-7 are spread via the saliva and nearly 100% of the population has been infected by early adulthood.

"It is possible that these patients harbor latent virus in the brain tissue that reactivates later in response to unknown triggers," said Leon Epstein, MD, a pediatric neurologist at the Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago. Dr. Epstein is the lead author of this new study published in the journal Epilepsia.

While febrile or fever-related seizures occur in 2-5% of infants, most of whom recover with no consequences, less is known about the outcome in children who suffer from the prolonged febrile seizures associated with HHV-6 or HHV-7. These children are still being followed and investigators expect that 30-40% of them will develop epilepsy within five years.

Currently infants with seizures are not tested for HHV-6B or HHV-7 and treatment consists of anti-seizure drugs. However, the authors expect clinical trials to be established as soon as more evidence is gathered. Transplant patients suffering with seizures from HHV-6 reactivation are routinely treated with antivirals and antiviral treatment is now common practice for symptomatic infants infected with a closely virus: cytomegalovirus or CMV (HHV-5). Infants who contract CMV from their mothers during pregnancy or shortly following birth can develop seizures and mental retardation as well as permanent losses in both hearing and vision. Antiviral therapy reduces neurological complications and seizures in these infants. The neurologists who conducted the study remain cautious about antiviral therapy. They note that the oral antiviral drug used to treat CMV infections, valganciclovir, can cause reversible neutropenia, a form of anemia; less toxic antivirals such as CMX001 are in the pipeline.

"HHV-6B can cause a strong cytokine response, and there is emerging data that inflammatory mechanisms may be involved in developing epilepsy after an insult such as a prolonged seizure," explained, Shlomo Shinnar, MD, PhD, of Montefiore Medical Center and Albert Einstein College of Medicine, and principal investigator of the study, "So it is possible that anti-inflammatory treatment could benefit these patients whether or not HHV-6B is the cause of the prolonged seizure. This is an area that needs further research.

Investigators will also be studying the roseola virus subset to determine if they develop cognitive problems in the years following the seizures. "We know that children and adults with temporal lobe epilepsy have cognitive problems. It will be interesting to see whether those who started out with an HHV-6B infection have more cognitive impairment down the road," said Shinnar.